113 related articles for article (PubMed ID: 24662560)
1. Nonvasculitic autoimmune meningoencephalitis after rituximab: the potential downside of depleting regulatory B cells in the brain.
Hadley I; Jain R; Sreih A
J Clin Rheumatol; 2014 Apr; 20(3):163-6. PubMed ID: 24662560
[TBL] [Abstract][Full Text] [Related]
2. Nonvasculitic autoimmune inflammatory meningoencephalitis.
Josephs KA; Rubino FA; Dickson DW
Neuropathology; 2004 Jun; 24(2):149-52. PubMed ID: 15139593
[TBL] [Abstract][Full Text] [Related]
3. Regression of white matter MRI abnormalities in nonvasculitic autoimmune inflammatory meningoencephalitis following intravenous immunoglobulin.
Imperiale D; Guastamacchia G; Duca S; Appendino L; Marietti G; Romito A; Atzori C; Buffa C
Eur Neurol; 2007; 57(4):244-5. PubMed ID: 17389804
[No Abstract] [Full Text] [Related]
4. Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia.
Otremba MD; Adam SI; Price CC; Hohuan D; Kveton JF
Am J Otolaryngol; 2012; 33(5):619-22. PubMed ID: 22361345
[TBL] [Abstract][Full Text] [Related]
5. A review of the current use of rituximab in autoimmune diseases.
Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
[TBL] [Abstract][Full Text] [Related]
6. Nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM): a reversible form of encephalopathy.
Caselli RJ; Boeve BF; Scheithauer BW; O'Duffy JD; Hunder GG
Neurology; 1999 Oct; 53(7):1579-81. PubMed ID: 10534272
[TBL] [Abstract][Full Text] [Related]
7. Nonvasculitic autoimmune inflammatory meningoencephalitis as a cause of potentially reversible dementia: report of 4 cases.
Lyons MK; Caselli RJ; Parisi JE
J Neurosurg; 2008 May; 108(5):1024-7. PubMed ID: 18447724
[TBL] [Abstract][Full Text] [Related]
8. [Safety of rituximab in patients with rheumatoid arthritis].
Morović-Vergles J
Reumatizam; 2010; 57(2):158-60. PubMed ID: 21875022
[TBL] [Abstract][Full Text] [Related]
9. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry.
Puéchal X; Gottenberg JE; Berthelot JM; Gossec L; Meyer O; Morel J; Wendling D; de Bandt M; Houvenagel E; Jamard B; Lequerré T; Morel G; Richette P; Sellam J; Guillevin L; Mariette X;
Arthritis Care Res (Hoboken); 2012 Mar; 64(3):331-9. PubMed ID: 22076726
[TBL] [Abstract][Full Text] [Related]
10. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.
Sellam J; Hendel-Chavez H; Rouanet S; Abbed K; Combe B; Le Loët X; Tebib J; Sibilia J; Taoufik Y; Dougados M; Mariette X
Arthritis Rheum; 2011 Apr; 63(4):933-8. PubMed ID: 21225699
[TBL] [Abstract][Full Text] [Related]
11. Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature.
Guidelli GM; Fioravanti A; Rubegni P; Feci L
Rheumatol Int; 2013 Nov; 33(11):2927-30. PubMed ID: 23135613
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab.
Salman-Monte TC; Lisbona MP; García-Retortillo M; Maymó J
Reumatol Clin; 2014; 10(3):196-7. PubMed ID: 24054835
[No Abstract] [Full Text] [Related]
13. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections.
Tesfa D; Ajeganova S; Hägglund H; Sander B; Fadeel B; Hafström I; Palmblad J
Arthritis Rheum; 2011 Aug; 63(8):2209-14. PubMed ID: 21560117
[TBL] [Abstract][Full Text] [Related]
14. Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium.
Gutierrez-Roelens I; Galant C; Theate I; Lories RJ; Durez P; Nzeusseu-Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR
Arthritis Rheum; 2011 May; 63(5):1246-54. PubMed ID: 21337318
[TBL] [Abstract][Full Text] [Related]
15. B-cell depletion in autoimmune diseases. Advances in autoimmunity.
Guzman Moreno R
Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204
[TBL] [Abstract][Full Text] [Related]
16. B-cell therapies in established rheumatoid arthritis.
Leandro MJ; Becerra-Fernandez E
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):535-48. PubMed ID: 22137923
[TBL] [Abstract][Full Text] [Related]
17. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
[TBL] [Abstract][Full Text] [Related]
18. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
[TBL] [Abstract][Full Text] [Related]
19. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D; Vangelista A; Pani A
G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
[TBL] [Abstract][Full Text] [Related]
20. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis.
Rosengren S; Wei N; Kalunian KC; Kavanaugh A; Boyle DL
Rheumatology (Oxford); 2011 Mar; 50(3):603-10. PubMed ID: 21098574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
